Withdrawal of Belviq and Belviq XR by Eisai
February 28, 2020
The FDA announced the request to voluntarily withdraw Belviq, Belviq XR (lorcaserin) from the U.S. market because a safety clinical trial showed an increased occurrence of cancer. Eisai, the manufacturer, has submitted a request to voluntarily withdraw the drug.
Clinical Services will be conducting a drug recall mailing to potentially impacted members and providers.
|Products||Belviq, Belviq XR|
|Withdrawal identification date||02/13/2020|
|Affected NDCs||62856-0529-60, 62856-0535-30|
|Look back period||10/16/2019 - 2/13/2020|
|Target population for clinical mailing||All|
|Mailing type||Members and Providers|
|Fulfillment due date for NCQA compliance||On or before: 3/4/2020|